Novo Nordisk A/S (NVO) to Issue Semi-annual Dividend of $0.51 on August 26th

Novo Nordisk A/S (NYSE:NVO) declared a semi-annual dividend on Tuesday, August 6th, Wall Street Journal reports. Investors of record on Friday, August 16th will be given a dividend of 0.5126 per share on Monday, August 26th. This represents a dividend yield of 0.7%. The ex-dividend date is Friday, August 16th.

Novo Nordisk A/S has increased its dividend by an average of 16.5% annually over the last three years. Novo Nordisk A/S has a dividend payout ratio of 24.3% meaning its dividend is sufficiently covered by earnings. Research analysts expect Novo Nordisk A/S to earn $4.35 per share next year, which means the company should continue to be able to cover its $1.03 annual dividend with an expected future payout ratio of 23.7%.

Novo Nordisk A/S Stock Up 0.4 %

Novo Nordisk A/S stock traded up $0.49 during mid-day trading on Wednesday, hitting $134.06. The company’s stock had a trading volume of 1,257,206 shares, compared to its average volume of 4,518,941. Novo Nordisk A/S has a 52-week low of $86.96 and a 52-week high of $148.15. The firm’s 50 day moving average is $137.29 and its 200 day moving average is $130.46. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The company has a market cap of $601.60 billion, a PE ratio of 46.04, a price-to-earnings-growth ratio of 1.33 and a beta of 0.41.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent research reports. BMO Capital Markets cut their price target on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 price target for the company. Argus raised their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, August 5th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $145.17.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.